Abstract
Murine fibrosarcoma cells (SSK) exhibit a transient cisplatin resistance after low-dose irradiation (5 x 2 Gy) in vitro and in vivo. When resistance is lost, it can be restored by a single drug exposure which, without preirradiation, does not generate cisplatin resistance in parental cells. There is no cross-resistance to radiation. Metallothioneins, which are associated with cisplatin resistance after high-dose irradiation (15 x 6 Gy), do not correlate with induction and loss of cisplatin resistance after low-dose irradiation. Since cisplatin survival curves are also monotonous when drug resistance diminishes, an adaptive response is more likely than a mutational event to underlie cisplatin-induced resistance. Drug resistance can be overcome by combined exposure to cisplatin in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX). Under these conditions, cisplatin sensitivity is increased 2.4- to 2.8-fold in the resistant strains compared with only 1.5- to 1.8-fold in the parental cells. The cellular platinum content with and without IBMX treatment is not significantly different in sensitive and resistant cells. Loss of drug resistance correlates with a decrease in cisplatin sensitisation by IBMX. This suggests that cisplatin resistance after low-dose irradiation may be associated with alterations of the cAMP-dependent signal transduction pathway.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., Kaye S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer. 1993 Oct 21;55(4):678–684. doi: 10.1002/ijc.2910550428. [DOI] [PubMed] [Google Scholar]
- Christen R. D., Jekunen A. P., Jones J. A., Thiebaut F., Shalinsky D. R., Howell S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest. 1993 Jul;92(1):431–440. doi: 10.1172/JCI116585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dempke W. C., Shellard S. A., Hosking L. K., Fichtinger-Schepman A. M., Hill B. T. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis. 1992 Jul;13(7):1209–1215. doi: 10.1093/carcin/13.7.1209. [DOI] [PubMed] [Google Scholar]
- Eichholtz-Wirth H., Hietel B. Heat sensitization to cisplatin in two cell lines with different drug sensitivities. Int J Hyperthermia. 1990 Jan-Feb;6(1):47–55. doi: 10.3109/02656739009140803. [DOI] [PubMed] [Google Scholar]
- Eichholtz-Wirth H., Reidel G., Hietel B. Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br J Cancer. 1993 May;67(5):1001–1006. doi: 10.1038/bjc.1993.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grunicke H., Hofmann J., Maly K., Uberall F., Posch L., Oberhuber H., Fiebig H. The phospholipid- and calcium-dependent protein kinase as a target in tumor chemotherapy. Adv Enzyme Regul. 1989;28:201–216. doi: 10.1016/0065-2571(89)90072-1. [DOI] [PubMed] [Google Scholar]
- Hamer D. H. Metallothionein. Annu Rev Biochem. 1986;55:913–951. doi: 10.1146/annurev.bi.55.070186.004405. [DOI] [PubMed] [Google Scholar]
- Hill B. T., Shellard S. A., Hosking L. K., Fichtinger-Schepman A. M., Bedford P. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):75–83. doi: 10.1016/0360-3016(90)90137-9. [DOI] [PubMed] [Google Scholar]
- Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
- Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
- LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
- Mann S. C., Andrews P. A., Howell S. B. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer. 1991 Jul 30;48(6):866–872. doi: 10.1002/ijc.2910480613. [DOI] [PubMed] [Google Scholar]
- Mellish K. J., Kelland L. R., Harrap K. R. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 1993 Aug;68(2):240–250. doi: 10.1038/bjc.1993.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Osmak M., Perovic S. Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1537–1541. doi: 10.1016/0360-3016(89)90959-0. [DOI] [PubMed] [Google Scholar]
- Otten A. D., Parenteau L. A., Døskeland S., McKnight G. S. Hormonal activation of gene transcription in ras-transformed NIH3T3 cells overexpressing RII alpha and RII beta subunits of the cAMP-dependent protein kinase. J Biol Chem. 1991 Dec 5;266(34):23074–23082. [PubMed] [Google Scholar]
- Petru E., Boike G., Sevin B. U. Potentiation of cisplatin cytotoxicity by methylxanthines in vitro. J Cancer Res Clin Oncol. 1990;116(5):431–433. doi: 10.1007/BF01612988. [DOI] [PubMed] [Google Scholar]
- Saburi Y., Nakagawa M., Ono M., Sakai M., Muramatsu M., Kohno K., Kuwano M. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res. 1989 Dec 15;49(24 Pt 1):7020–7025. [PubMed] [Google Scholar]
- Sklar M. D., Prochownik E. V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 1991 Apr 15;51(8):2118–2123. [PubMed] [Google Scholar]
- Teicher B. A., Herman T. S., Holden S. A., Wang Y. Y., Pfeffer M. R., Crawford J. W., Frei E., 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1457–1461. doi: 10.1126/science.247.4949.1457. [DOI] [PubMed] [Google Scholar]
- Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969 Mar;27(3):502–522. doi: 10.1016/0003-2697(69)90064-5. [DOI] [PubMed] [Google Scholar]
- Tishler R. B., Calderwood S. K., Coleman C. N., Price B. D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 1993 May 15;53(10 Suppl):2212–2216. [PubMed] [Google Scholar]
- Twentyman P. R., Wright K. A., Rhodes T. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):217–220. doi: 10.1016/0360-3016(91)90093-j. [DOI] [PubMed] [Google Scholar]
- Zhen W., Link C. J., Jr, O'Connor P. M., Reed E., Parker R., Howell S. B., Bohr V. A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 1992 Sep;12(9):3689–3698. doi: 10.1128/mcb.12.9.3689. [DOI] [PMC free article] [PubMed] [Google Scholar]